The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Topoisomerase II and chemosensitivity for pegylated liposomal doxorubicin (pld) used in the third-line treatment of patients with metastatic bladder cancer.
A. Rozzi
No relevant relationships to disclose
A. P. Mancuso
No relevant relationships to disclose
F. Recine
No relevant relationships to disclose
C. Nardoni
No relevant relationships to disclose
M. Corona
No relevant relationships to disclose
M. R. Restuccia
No relevant relationships to disclose
M. Salerno
No relevant relationships to disclose
F. Bordin
No relevant relationships to disclose
T. Falbo
No relevant relationships to disclose
G. Lanzetta
No relevant relationships to disclose